Glucocorticoid-Induced Osteoporosis

被引：147

作者：

Weinstein R.S. ^{[1
,2
]}

机构：

[1] Department of Internal Medicine, Ctr. Osteoporosis Metab. Bone Dis., Univ. of Arkansas for Med. Sciences, Little Rock

[2] Univ. of Arkansas for Med. Sciences, Little Rock, AR 72205-7199, 4301 West Markham Street

来源：

Reviews in Endocrine and Metabolic Disorders | 2001年 / 2卷 / 1期

基金：

美国国家卫生研究院;

关键词：

Apoptosis; Bone formation; Bone marrow cells; Osteoblasts; Osteoclasts; Osteocytes; Remodeling;

D O I：

10.1023/A:1010007108155

中图分类号：

学科分类号：

摘要：

During normal bone remodeling, the supply of new osteoblasts and osteoclasts and the timing of the death of osteoclasts, osteoblasts and osteocytes by apoptosis are critical determinants of the initiation of new BMUs and the extension or reduction of the lifetime of existing ones. Many of the effects of chronic glucocorticoid administration on bone can be explained by decreased birth of osteoblast and osteoclast precursors and increased apoptosis of mature osteoblasts and osteocytes, disrupting the fine balance among these processes. Therapeutic agents that alter the prevalence of apoptosis of osteoblasts and osteoclasts can correct the imbalance in cell numbers that is the basis of the diminished bone mass and increased risk of fractures found in glucocorticoid-induced osteoporosis.

引用

页码：65 / 73

页数：8

共 37 条

[1]

Cushing H., The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism), Bull Johns Hopkins Hosp, 50, pp. 137-195, (1932)

[2]

Fitzpatrick L.A., Glucocorticoid-induced osteoporosis, Osteoporosis, pp. 202-226, (1994)

[3]

Reid I.R., Pathogenesis and treatment of steroid osteoporosis, Clin Endocrinol, 30, pp. 83-103, (1989)

[4]

LoCascio V., Bonucci E., Imbimbo B., Ballanti P., Adami S., Milani S., Tartarotti D., DellaRocca C., Bone loss in response to long-term glucocorticoid therapy, Bone Miner, 8, pp. 39-51, (1990)

[5]

Lukert B.P., Kream B.E., Clinical and basic aspects of glucocorticoid action in bone, Principles of Bone Biology, pp. 533-548, (1996)

[6]

Mankin H.E., Nontraumatic necrosis of bone (osteonecrosis), N Engl J Med, 326, pp. 1473-1479, (1992)

[7]

Reid I.R., Preventing glucocorticoid-induced osteoporosis, N Engl J Med, 327, pp. 420-421, (1997)

[8]

Hahn T.J., Halstead L.R., Baran D.T., Effects of short term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentrations in man, J Clin Endocrinol Metab, 52, pp. 111-115, (1981)

[9]

Paz-Pacheco E., Fuleihan G.E.-H., Leboff M.S., Intact parathyroid hormone levels are not elevated in glucocorticoid-treated subjects, J Bone Miner Res, 10, pp. 1713-1718, (1995)

[10]

Prummel M.F., Wiersinga W.M., Lips P., Sanders G.T.B., Sauerwein H.P., The course of biochemical parameters of bone turnover during treatment with corticosteroids, J Clin Endocrinol Metab, 72, pp. 382-386, (1991)

← 1 2 3 4 →